US Bioservices now dispenses ONPATTRO

August 13, 2018

The U.S. Food and Drug Administration has recently approved ONPATTRO (patisiran) for the treatment of adults with hereditary ATTR (hATTR) amyloidosis with symptomatic polyneuropathy.